Results 201 to 210 of about 159,908 (305)

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden   +3 more
wiley   +1 more source

Older Adults' Access to Pharmacological Treatment, a Human Right to Health: Scoping Review (2020-2025). [PDF]

open access: yesPharmacy (Basel)
Cardona D   +6 more
europepmc   +1 more source

We ought to discuss the social construction of cadavers: Here's why and how

open access: yes
Anatomical Sciences Education, EarlyView.
Fatima Ehsan, Susan Lamb
wiley   +1 more source

Clinician's attitudes & perspective on chemical adherence testing in hypertension (CATCH): A qualitative interview study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Chemical Adherence Testing (CAT) is gaining prominence as a reliable and valid clinical method to detect whether antihypertensive agents are being taken as prescribed. This study aimed to explore clinicians' attitudes and perspectives on the clinical use of CAT.
Roshan Shahab   +2 more
wiley   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy